Last reviewed · How we verify
IT-pIL12-EP
At a glance
| Generic name | IT-pIL12-EP |
|---|---|
| Also known as | intratumoral plasmid-IL-12 + Electroporation |
| Sponsor | OncoSec Medical Incorporated |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IT-pIL12-EP CI brief — competitive landscape report
- IT-pIL12-EP updates RSS · CI watch RSS
- OncoSec Medical Incorporated portfolio CI